Lucentis is a trade name of Ranibizumab indicated for the treatment of conditions such as Wet Age-related Macular Degeneration (wAMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Myopic Choroidal Neovascularization (mCNV) and Macular Edema following Retinal Vein Occlusion (RVO). Other drugs used for treating Wet Age-related Macular Degeneration (wAMD) are Avastin and Eylea.

The top two retinal diseases that affect a large proportion of the Medicare population are age-related macular degeneration (AMD) and diabetic retinopathy and both diseases limit patients’ sight.

Healthcare professionals use HCPCS code J2778 - Injection, Ranibizumab, 0.1 MG to get reimbursement from the payers. Dexur analysed Medicare claims data (Jul 2017 to Jun 2018) with regards to avg.payout of Lucentis from Medicare for both professional claims and Outpatient Institutional claims.

Lucentis received an average payment of $1,534 on professional claims whereas the Outpatient institutional claims received $1,418 as an average payment from Medicare.

Dexur also has a more in depth database of patients who have Wet Age-related Macular Degeneration (wAMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Myopic Choroidal Neovascularization (mCNV) and Macular Edema following Retinal Vein Occlusion (RVO) and can benefit from the usage of Lucentis.

Dexur Pro members get access to data related to Claims & Beneficiaries, top diagnosis, specialty, place of service, payment utilization etc.